Bio-Thera Solutions Ltd (688177) - Total Assets
Based on the latest financial reports, Bio-Thera Solutions Ltd (688177) holds total assets worth CN¥2.25 Billion CNY (≈ $328.76 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See net assets of Bio-Thera Solutions Ltd for net asset value and shareholders' equity analysis.
Bio-Thera Solutions Ltd - Total Assets Trend (2016–2024)
This chart illustrates how Bio-Thera Solutions Ltd's total assets have evolved over time, based on quarterly financial data.
Bio-Thera Solutions Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Bio-Thera Solutions Ltd's total assets of CN¥2.25 Billion consist of 40.3% current assets and 59.7% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 13.1% |
| Accounts Receivable | CN¥104.15 Million | 4.7% |
| Inventory | CN¥253.10 Million | 11.5% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥224.10 Million | 10.2% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2016–2024)
This chart illustrates how Bio-Thera Solutions Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Bio-Thera Solutions Ltd market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Bio-Thera Solutions Ltd's current assets represent 40.3% of total assets in 2024, a decrease from 46.9% in 2016.
- Cash Position: Cash and equivalents constituted 13.1% of total assets in 2024, up from 1.2% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 10.0% of total assets, an increase from 0.0% in 2016.
- Asset Diversification: The largest asset category is inventory at 11.5% of total assets.
Bio-Thera Solutions Ltd Competitors by Total Assets
Key competitors of Bio-Thera Solutions Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Bio-Thera Solutions Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.79 | 1.05 | 6.92 |
| Quick Ratio | 0.56 | 0.82 | 6.67 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥-244.58 Million | CN¥45.08 Million | CN¥1.25 Billion |
Bio-Thera Solutions Ltd - Advanced Valuation Insights
This section examines the relationship between Bio-Thera Solutions Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 20.27 |
| Latest Market Cap to Assets Ratio | 0.57 |
| Asset Growth Rate (YoY) | -3.6% |
| Total Assets | CN¥2.21 Billion |
| Market Capitalization | $1.25 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Bio-Thera Solutions Ltd's assets below their book value (0.57x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Bio-Thera Solutions Ltd's assets decreased by 3.6% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Bio-Thera Solutions Ltd (2016–2024)
The table below shows the annual total assets of Bio-Thera Solutions Ltd from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥2.21 Billion ≈ $322.74 Million |
-3.57% |
| 2023-12-31 | CN¥2.29 Billion ≈ $334.67 Million |
+4.93% |
| 2022-12-31 | CN¥2.18 Billion ≈ $318.96 Million |
-16.73% |
| 2021-12-31 | CN¥2.62 Billion ≈ $383.06 Million |
+9.39% |
| 2020-12-31 | CN¥2.39 Billion ≈ $350.19 Million |
+135.93% |
| 2019-12-31 | CN¥1.01 Billion ≈ $148.43 Million |
-0.63% |
| 2018-12-31 | CN¥1.02 Billion ≈ $149.37 Million |
+64.92% |
| 2017-12-31 | CN¥618.94 Million ≈ $90.57 Million |
-12.61% |
| 2016-12-31 | CN¥708.29 Million ≈ $103.65 Million |
-- |
About Bio-Thera Solutions Ltd
Bio-Thera Solutions, Ltd., a biopharmaceutical company, researches and develops novel therapeutics for the treatment of cancer, autoimmune, cardiovascular, eye diseases, and other severe unmet medical needs in China and internationally. It offers QLETLI for the treatment of ankylosing spondylitis, rheumatoid arthritis, psoriasis, Crohn's disease, and uveitis; POBEVCY to treat patients with metast… Read more